First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent

被引：6
作者：
Floyd, Mark [1 ]
El Osta, Badi [1 ]
Tang, Shou-Ching [1 ,2 ]
机构：
[1] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA
[2] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF GLOBAL ONCOLOGY | 2016年 / 4卷
关键词：
D O I：
10.1200/JGO.2016.007492
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 5 条
[1]   Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].
Bertrand, Anne ;
Kostine, Marie ;
Barnetche, Thomas ;
Truchetet, Marie-Elise ;
Schaeverbeke, Thierry .
BMC MEDICINE, 2015, 13
[2]   Indoleamine 2,3-dioxygenase and tumor-induced tolerance [J].
Munn, David H. ;
Mellor, Andrew L. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1147-1154
[3]   Indoleamine 2,3 dioxygenase and metabolic control of immune responses [J].
Munn, David H. ;
Mellor, Andrew L. .
TRENDS IN IMMUNOLOGY, 2013, 34 (03) :137-143
[4]   Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach [J].
Szabo, Nikoletta ;
Kincses, Zsigmond Tamas ;
Toldi, Jozsef ;
Vecsei, Laszlo .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 310 (1-2) :256-260
[5]   A phase 2 randomized trial of the 100 pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data [J].
Tang, S-C ;
Montero, A. ;
Munn, D. ;
Link, C. ;
Vahanian, N. ;
Kennedy, E. ;
Soliman, H. .
CANCER RESEARCH, 2016, 76
1